title: Improving growth in children with inflammatory bowel disease.
abstract: BACKGROUND
  Growth in children with inflammatory bowel disease (IBD) is affected through a number of mechanisms; controlling disease activity and supporting poor nutritional status are paramount in these patients. Further understanding of the basic mechanisms by which cytokines influence growth will facilitate the development of therapeutic modalities to improve growth.
  
  
  CONCLUSIONS
  Clinical management that addresses growth and puberty in children with IBD should be a partnership between paediatric gastroenterologists and endocrinologists. Well-designed studies of growth-promoting hormonal treatment may answer questions regarding the efficacy and safety of treating growth retardation in the subgroup of patients who continue to fail to grow despite optimal management of their IBD.
authors.affiliation: Bone & Endocrine Research Group, University of Glasgow, Glasgow, UK. gcl328@clinmed.gla.ac.uk
authors.forename: S Faisal
authors.initials: SF
authors.lastname: Ahmed
authors.forename: Jarod S C
authors.initials: JS
authors.lastname: Wong
authors.forename: Paraic
authors.initials: P
authors.lastname: McGrogan
mesh_terms: D000075202:Contraindications; D016207:Cytokines / Q000378:metabolism; D005938:Glucocorticoids; D006128:Growth; D006130:Growth Disorders / Q000209:etiology; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000503:physiopathology*; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D005938:Glucocorticoids; D018836:Inflammation Mediators; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I